Relapsed Disease

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

By

Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.

A Rare Case of Simultaneous Second Malignancies in Relapsed Multiple Myeloma

A Rare Case of Simultaneous Second Malignancies in Relapsed Multiple Myeloma

By

A first-reported case of simultaneous intracranial plasmacytoma and malignant pericardial effusion in a woman with relapsed multiple myeloma previously treated with chemotherapy and allogenic HSCT is described.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs